

血浆 IIA 分泌型磷脂酶 A2 水平与冠脉支架术后再狭窄关系

高应东¹ 夏永祥¹ 张瑞生¹ 朱成宾¹ 赵昕亚¹ 肖平喜^{2△}

(南京医科大学附属南京第一医院 1.检验科 2.心内科 江苏 南京 210006)

摘要 目的:测定稳定型冠心病患者支架植入术(percutaneous coronary intervention,PCI)前血浆 IIA 分泌型磷脂酶 A2(group IIA secretory phospholipase A2, A-sPLA2)的水平,以探讨该酶与冠脉支架术后再狭窄的可能关系。方法:稳定型冠心病行 PCI 患者 63 例,非冠心病患者 39 例,健康正常对照组 42 例,分别取外周静脉血测定血浆 A-sPLA2 酶浓度。PCI 患者 6 个月后复查造影。结果:PCI 患者术前该酶浓度显著高于正常对照组($P<0.05$),支架内再狭窄率 34.9%,再狭窄(restenosis,RS)患者支架术前该酶水平与无再狭窄患者该酶水平无统计学差异($P>0.05$)。结论:PCI 患者术前血浆 A-sPLA2 酶浓度显著高于正常对照组,但可能与支架术后再狭窄无关。

关键词: A 分泌型磷脂酶 A2;高敏 C-反应蛋白;支架植入术;再狭窄

中图分类号: R541.4 **文献标识码:** A **文章编号:** 1673-6273(2011)19-3666-03

Relationship Between Plasma IIA Secretory Phospholipase A2 and Restenosis after Percutaneous Coronary Intervention in Patients with Coronary Heart Disease

GAO Ying-dong¹, XIA Yong-xiang¹, ZHANG Rui-sheng¹, ZHU Cheng-bin¹, ZHAO Xin-ya¹, XIAO Ping-xi^{2△}

(Nanjing Medical University, Affiliated Nanjing First Hospital, Department of 1.Clinical Laboratory, 2.Cardiology, Nanjing, 210006, China)

ABSTRACT Objective: To study the correlation between IIA-sPLA2 level and restenosis after percutaneous coronary intervention (PCI) in Patients with coronary heart disease. **Methods:** This study enrolled 63 patients with coronary heart disease (CHD) who underwent successful PCI, 39 patients with non-CHD, and 42 healthy subjects were studied as a control group. Levels of IIA-sPLA2 in plasma were measured by an enzyme immunoassay using a monoclonal antibody. The patients who underwent PCI had repeat angiography at six-month follow-up. **Results:** The level of IIA-sPLA2 in PCI patients was significantly higher than that in healthy subjects ($P<0.05$), but not higher than that in patients with non-CHD ($P>0.05$). Restenosis occurred in 22 patients (34.9%). While there were no significant changes of the levels of IIA-sPLA2 between the patients without or with restenosis. **Conclusions:** The level of IIA-sPLA2 in patients with coronary heart disease had a significant increase compared to the healthy subjects, but such increase may not be associated with in-stent restenosis.

Key words: Group IIA secretory phospholipase A2; High sensitive C-reactive protein; Percutaneous coronary intervention; Restenosis

Chinese Library Classification(CLC): R541.4 **Document code:** A

Article ID: 1673-6273(2011)19-3666-03

前言

冠心病患者支架植入术成为临床上治疗冠心病的重要手段之一,但是术后再狭窄严重影响其远期疗效^[1],炎症可能参与了再狭窄的全过程^[2]。血浆 A 分泌型磷脂酶 A2 作为一个炎症因子,在动脉粥样硬化发生发展过程中可能起了重要作用^[3],本文探讨冠心病患者 PCI 术前该酶浓度与再狭窄的可能关系。

1 资料和方法

1.1 临床资料

2009 年 2 月至 2010 年 2 月在我院心内科住院,并接受普通支架植入术的稳定型冠心病患者 63 例(PCI 组),男性 43

例,女性 20 例,平均年龄(65.37 ± 9.76)岁。入选标准:①有临床症状;②冠状动脉主要血管(即左主干、前降支、回旋支、右冠状动脉)罪犯血管(target vascular)管腔狭窄程度 $\geq 75\%$ 。排除标准:急性冠脉综合征、近期外科手术或创伤、此前 1 个月内患有严重的感染性疾病、恶性肿瘤、慢性炎症性疾病(包括类风湿性关节炎、骨关节炎、肠炎等)、慢性结缔组织病等。非冠心病组:同期因胸痛或 ECG 显示有局部缺血改变,经冠脉造影显示为正常冠脉或狭窄 $<50\%$,共 39 例,男性 18 例,女性 21 例,年龄(62.03 ± 9.27)岁,正常对照组 42 例选自我院健康体检者,男性 17 例,女性 25 例,年龄(64.17 ± 10.83)岁。所有 PCI 患者 6 个月后复查冠脉造影,再狭窄标准^[4]:冠脉造影显示支架内管腔狭窄超过内径的 50%。正常对照组及实验组基本情况见表 1。

1.2 方法

A-sPLA2:人 A-sPLA2 定量检测(ELISA)试剂盒,R&D 公司产品,BIO-RAD Model 680 型酶标仪测定。总胆固醇(TC)、甘油三酯(TG)为北京中生北控公司产品,采用酶法;高

作者简介:高应东(1973-),男,医学硕士,主管技师,主要研究方向:生化诊断。电话:025-52271422 E-mail: jlydq@126.com
△通讯作者:肖平喜 E-mail: sysu-xiao@163.com
(收稿日期:2011-02-12 接受日期:2011-03-06)

密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)为日本第一化学公司产品,采用酶法;血糖(Glu)为上海德赛公司产品,己糖激酶法;肌酐(Cre)为四川迈克科技股份有限公司产品,酶法测定;高敏C反应蛋白(high sensitive C-Reactive Protein, hs-CRP)为芬兰 ORION 公司产品,采用胶乳增强免疫比浊法,以上指标均由 Olympus AU5400 全自动生化分析仪测定。

表 1 正常对照组及实验组基本情况($\bar{x} \pm s$)
Table 1 Baseline characteristics of control and study groups

Item	Control group(n=42)	Non-CHD group(n=39)	CHD with PCI group(n=63)
Male(%)	17(40.5%)	18(46.2%)	43(68.3%)
Age(yrs)	64.17± 10.83	62.03± 9.27	65.37± 9.76
Glu(mmol/L)	5.33± 0.76	6.37± 1.69*	7.55± 3.94*
Cre(μmmol/L)	67.28± 19.05	86.69± 26.43*	93.56± 25.68*
TC(mmol/L)	4.80± 0.72	4.28± 0.74*	4.35± 1.04*
TG(mmol/L)	1.05± 0.35	1.23± 0.61	1.54± 1.06*
HDL-C(mmol/L)	1.42± 0.20	1.12± 0.32*	1.00± 0.27*
LDL-C(mmol/L)	2.42± 0.83	2.61± 0.74	2.84± 1.00

注: *与正常对照组比较 $P<0.05$
Note: * $P<0.05$ Compared with Control group

1.3 统计学处理

使用 SPSS 11.0 软件进行统计分析, 偏态分布资料以中位数(四分位数间距)表示, 正态分布资料以均数± 标准差($\bar{x} \pm s$)表示, 均数比较采用 F 检验及 t 检验; A-sPLA2 与 hs-CRP 之间关系采用等级相关检验, 通过受试者工作曲线(ROC 曲线)判断其诊断价值。以 $P<0.05$ 为有统计学差异。

2 结果

2.1 三组血浆 A-sPLA2 浓度和 hs-CRP 浓度比较

血浆 A-sPLA2 浓度和 hs-CRP 浓度比较见表 2。非冠心病组及冠心病 PCI 组血浆 A-sPLA2 浓度均显著高于正常对照组($P<0.05$), 而冠心病 PCI 组与非冠心病组间无统计学差异($P>0.05$)。冠心病 PCI 组 hs-CRP 浓度显著高于正常对照组($P<0.05$), 非冠心病组 hs-CRP 浓度与正常对照组及冠心病 PCI 组间均无统计学意义($P>0.05$)。

表 2 血浆 A-sPLA2 浓度和 hs-CRP 浓度比较
Table 2 Levels of A-sPLA2 and hs-CRP compared with each other

Item	Control group(n=42)	Non-CHD group(n=39)	CHD with PCI group(n=63)
A-sPLA2(pg/mL)	178(138,218)	334(183,442)*	345(231,399)*
Hs-CRP(mg/L)	1.88± 2.47	2.25± 3.88	3.87± 4.86*

注: *与正常对照组比较 $P<0.05$
Note: * $P<0.05$ Compared with Control group

2.2 正常对照组、非冠心病组、PCI 再狭窄组及 PCI 无再狭窄组血浆 A-sPLA2 浓度及血清 hs-CRP 浓度比较

所有 PCI 患者 6 个月后复查冠脉造影, 共有 22 例发生再

狭窄, 再狭窄率 34.9%。四组间血浆 A-sPLA2 浓度及血清 hs-CRP 浓度比较见图 1、图 2。




图 1 各组间血浆 A-sPLA2 浓度比较
Fig.1 The comparison on levels of A-sPLA2 in plasma for each group




图 2 各组间血清 hs-CRP 浓度比较
Fig.2 The comparison on levels of hs-CRP in serum for each group

2.3 A-sPLA2 及 hs-CRP 的 ROC 曲线

A-sPLA2 及 hs-CRP 对冠心病的诊断价值 (ROC 曲线)

见图 3。




图 3 A-sPLA2 及 hs-CRP 的 ROC 曲线

Fig.3 The ROC Curves of A-sPLA2 and hs-CRP

3 讨论

A-sPLA2 作为磷脂酶 A2 家族成员,它能水解细胞膜和脂蛋白磷脂 2 位(Sn2)脂键^[5],从而产生游离脂肪酸和溶血卵磷脂,水解产物又可以被进一步代谢为广泛参与细胞内各种炎症变化的介质^[6]。冠心病的炎症发病机制在临床正广泛受到关注,国内外研究显示,心血管疾病患者 A-sPLA2 血浆浓度是增高的,高浓度的 A-sPLA2 是一个独立危险因子和重要的预测因子^[7-11]。本文也显示冠心病 PCI 组及非冠心病组血浆 A-sPLA2 浓度均显著高于健康对照组,但是冠心病 PCI 组酶浓度虽高于非冠心病组,但是两组之间并无统计学差异,也就是说 A-sPLA2 在区分有冠心病及无冠心病方面价值甚小,从 ROC 曲线下面积也可看出,其对于冠心病的诊断价值低于 hs-CRP (曲线下面积分别为 0.509 与 0.657)。

血管内再狭窄已经成为影响血管修复术长期疗效的一个重要限制因素,冠脉支架的广泛应用也导致了一个更加剧烈和长期的炎症状态^[12]。sPLA2 不仅是一个炎症标志物,而且它可能直接参与了再狭窄的进展^[13]。国外研究^[14-16]也阐明了 A-sPLA2 与 RS 的可能关系,但是本文 PCI 再狭窄组 A-sPLA2 浓度并不高于无再狭窄组,可能与本研究病例数太少,研究对象产生偏倚所致。同时对 A-sPLA2 及 hs-CRP 进行 Spearman 等级相关检验,发现二者间并无相关性。

总之,冠心病是一个多因素复杂疾病,支架后再狭窄机制复杂^[17],现今关于炎症因子与再狭窄关系研究较多,炎症因子在再狭窄中的预测价值还有赖于大样本、科学严谨的临床试验加以验证。

参考文献(References)

[1] 杨俊娟,罗奕龙,高炜等.血红素氧合酶 1 基因多态性与冠状动脉支架后再狭窄相关[J].中国动脉硬化杂志,2005,13(1):91-93
Yang Jun-juan, Luo Yi-long, Gao Wei et al. Microsatellite Polymorphism in the Heme Oxygenase-1 Gene Promotor Associated with Restenosis After Percutaneous Coronary Intervention[J]. Chinese Journal of Arteriosclerosis, 2005, 13(1):91-93

[2] Farb A, Weber DK, Kolodgie FD, et al. Morphological predictors of restenosis after coronary stenting in humans[J]. Circulation, 2002, 105(25):2974-2980

[3] Ibeas E, Fuentes L, Martí n R, et al. Secreted phospholipase A2 type IIA as a mediator connecting innate and adaptive immunity: new role in atherosclerosis[J]. Cardiovasc Res, 2009, 81(1):54-63

[4] 付剑云,苏又苏,吴京兰等.冠脉支架术前、术后血清 sCD40L 水平与再狭窄的关系[J].实用全科医学杂志,2007,5(3):193-194
Fu Jian-yun, Su You-su, Wu Jing-lan, et al. Serum Soluble CD40 Ligand and its Relation to Restenosis before and after Coronary Stent Implantation in Patients with Coronary Heart Disease[J]. Applied Journal of General Practice, 2007, 5(3):193-194

[5] 周秀萍,高应东,彭怀燕. A 分泌型磷脂酶 A2 与心血管疾病[J]. 中国动脉硬化杂志,2005,13(2):239-241
Zhou Xiu-ping, Gao Ying-dong, Peng Huai-yan. Group IIA secretory Phospholipase A2 and Cardiovascular Disease [J]. Chinese Journal of Arteriosclerosis, 2005, 13(2):239-241

[6] Chait A, Han CY, Oram JF, et al. Thematic review series: The immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? [J]. J Lipid Res, 2005, 46(3):389-403

[7] 高应东,夏永祥,张瑞生等. 血浆 IIA 分泌型磷脂酶 A2 与冠心病相关性研究[J]. 中国误诊学杂志,2008,8(6):1275-1277
Gao Ying-dong, Xia Yong-xiang, Zhang Rui-sheng, et al. Study on Relationship Between Plasma Group IIA secretory Phospholipase A2 and Coronary Heart Disease [J]. Chinese Journal of Misdiagnostics, 2008, 8(6):1275-1277

[8] Niessen HW, Krijnen PA, Visser CA, et al. Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes? [J]. Cardiovasc Res, 2003, 60(1):68-77

[9] Kugiyama K, Ota Y, Takazoe K, et al. Circulating levels of secretory type II phospholipase A2 predict coronary events in patients with coronary artery disease[J]. Circulation, 1999, 100(12):1280-1284

[10] Porela P, Pulkki K, Voipio-Pulkki LM, et al. Level of circulating phospholipase A2 in prediction of the prognosis of patients with suspected myocardial infarction [J]. Basic Res Cardiol, 2000, 95(5):413-417

[11] Kugiyama K, Ota Y, Kawano H, et al. Increase in plasma levels of secretory type II phospholipase A2 in patients with coronary spastic angina[J]. Cardiovasc Res, 2000, 47(1):159-165

[12] Welt FG, Rogers C. Inflammation and restenosis in the stent era[J]. Arterioscler Thromb Vasc Biol, 2002, 22(11):1769-1776

[13] 高应东,陈雨欣,夏永祥. 血浆 A 分泌型磷脂酶 A2 在心血管疾病及支架后再狭窄中作用[J]. 中国动脉硬化杂志,2009,17(10):874-876
Gao Ying-dong, Chen Yu-xin, Xia Yong-xiang. Effects of Plasma Group IIA secretory Phospholipase A2 in Cardiovascular Disease and in Restenosis after Percutaneous Coronary Intervention [J]. Chinese Journal of Arteriosclerosis, 2009, 17(10):874-876

[14] Korotaeva AA, Provatorov SI, Samoilova EV, et al. Serum level of secretory phospholipase A2 (sPLA2) as a predictor of restenosis after coronary angioplasty [J]. Ter Arkh, 2002, 74(4):12-15

(下转第 3733 页)

导。同时,医院也可以主动组织医护人员及患者与厂商进行交流。

参考文献(References)

- [1] 林吉跃,张育纯.建立健全医疗设备医用耗材管理制度[J].现代医学仪器与应用,2007(2):48-50
Lin Jiyue, Zhang Yuchun. Establishing and Improving the Medical Devices and Consumables Management System [J]. Modern Medical Equipment and Application,2007(2):48-50(In Chinese)
- [2] 王冠. 试论当前医院医疗设备的采购与管理 [J]. 经营管理者,2009 (16):92
Wang Guan. Remark on the Purchase and Management of Medical Devices in Current Hospitals [J].Manager' Journal, 2009 (16):92(In Chinese)
- [3] 黄良谋, 陈华英. 论如何加强高值医疗耗材的管理 [J]. 中国医院, 2005,9(1):36-38
Huang Liangmou, Chen Huaying. Control of High Cost Medical Disposable[J]. Chinese Hospitals,-2005,9(1):36-38(In Chinese)
- [4] 顾伟.浅谈我院医用耗材的采购管理[J].中国医疗设备,2009,24(12): 73-74,98
Gui Wei. Discussion on the Purchase Management of Medical Consumables in Our Hospital [J]. China Medical Devices, 2009,24(12): 73-74,98(In Chinese)
- [5] 付礼霞,郭玉军.医疗设备与耗材招标过程中的常见问题及如何避免[J].医疗装备,2006,19(10):30-31
Fu Lixia, Guo Yujun. Common Problems and Their Solutions in the Bidding Process of Medical Devices and Consumables [J]. Chinese Journal of Medical Device,2006,19(10):30-31(In Chinese)
- [6] 王芳,于润吉.医院专用医疗设备流向全程管理研究[J].卫生经济研究,2011(5):45-46
Wang Fang, Yu Runjie. Research on the Whole Management Process of the Flow of Special Medical Equipment in Hospitals[J]. Health Economics Research,2011(5):45-46(In Chinese)
- [7] 高华敏. 浅析医疗耗材采购形式 [J]. 医疗卫生装备,2011,32(4): 105-106
Gao Huaming. Purchase Form of Medical Consumable [J]. Chinese Medical Equipment Journal,2011,32(4):105-106(In Chinese)
- [8] 陈宏文,廖伟光,夏景涛.医疗设备售后服务质量的现状与对策探讨[J].中国医疗设备,2011,26(5):110-111
Chen Hongwen, Liao Weiguang, Xia Jingtao. The Current Situation and Policies of After-sale Service Quality of Medical Equipment[J]. China Medical Devices, 2011, 26(5):110-111(In Chinese)
- [9] 许迎新. 浅谈国产医疗设备在医疗市场的现状 [J]. 医疗装备,2002 (11):41
Xu Yingxin. Current Situation of Domestic Medical Devices in Medical Market [J]. Chinese Journal of Medical Device,2002(11):41 (In Chinese)
- [10] 黎明.国产医疗设备为何不敌舶来品[N].健康报, 2003-07-21
Li Ming. The Reasons Why Domestic Medical Devices Are Lost to Imported Ones[N]. Jian Kang Bao, 2003-07-21(In Chinese)
- [11] 郭时民.国产医械:打铁还要自身硬[N].中国医药报, 2006-02-28 (B08)
Wu Shiming. Domestic Medical Devices: the One Who Strike the Iron Needs to Be Strong Himself [N].China Pharmaceutical News, 2006-02-28(B08)(In Chinese)
- [12] 郑小溪,陆庆生,姜天.国产医疗设备对于减少患者医疗费用的重要作用[J].医疗卫生装备,2010,31(11):120-121
Zheng Xiaoxi, Lu Qingsheng, Jiang Tian. Importance of Domestic Medical Equipment on Reducing Patients' Fee-for-service[J]. Chinese Medical Equipment Journal, 2010,31(11):120-121(In Chinese)
- [13] 廖雪峰,黄秀凤.加强医院购置进口设备管理的思考[J].经济师, 2007(2):59
Liao Yunfeng, Huang Xiufeng. Suggestions on Strengthening the Management of Hospital Purchasing Imported Devices [J]. China Economist,2007(2):59(In Chinese)
- [14] 卫生部.医疗卫生机构医学装备管理办法[Z].2011-03-24
Ministry of Health. Approaches for Management of Medical Devices by Medical and Health Institutions[Z]. 2011-03-24(In Chinese)
- [15] 财政部,科技部,国家发展改革委,海关总署,国家税务总局.关于科技重大专项进口税收政策的通知[Z].〔2010〕28 号
Ministry of Finance, Ministry of Science and technology, State Development and Reform Commission, General Administration of Customs, State Administration of Taxation. Notices on Tax Policy for Major Science and Technology Import[Z].〔2010〕NO.28(In Chinese)

(上接第 3668 页)

- [15] Liu PY, Li YH, Tsai WC, et al. Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention[J]. Eur Heart J, 2003,24 (20):1824-1832
- [16] Korotaeva AA, Samoilova EV, Kaminny AI, et al. The catalytically active secretory phospholipase A2 type IIA is involved in restenosis development after PTCA in human coronary arteries and generation of atherogenic LDL[J]. Mol Cell Biochem, 2005 ,270(1-2):107-113
- [17] 李晓涛,夏岳.炎症反应在冠脉支架置入术后再狭窄中的研究进展[J].心血管病学进展杂志, 2007 ,26(5) :703-706
Li Xiao-tao, Xia Yue. Inflammatory Mechanism of Coronary Restenosis[J]. Adv Cardiovasc Dis, 2007, 26(5):703-706